Head-To-Head Contrast: Cyclacel Pharmaceuticals (NASDAQ:BGMS) & Ferguson (NYSE:FERG)
by Mitch Edgeman · The Markets DailyFerguson (NYSE:FERG – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) are both industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.
Institutional & Insider Ownership
82.0% of Ferguson shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 0.2% of Ferguson shares are held by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Ferguson has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Ferguson and Cyclacel Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ferguson | 0 | 6 | 12 | 1 | 2.74 |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Ferguson currently has a consensus target price of $287.44, suggesting a potential upside of 20.75%. Given Ferguson’s stronger consensus rating and higher possible upside, analysts clearly believe Ferguson is more favorable than Cyclacel Pharmaceuticals.
Earnings & Valuation
This table compares Ferguson and Cyclacel Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ferguson | $31.32 billion | 1.47 | $1.86 billion | $8.51 | 27.97 |
| Cyclacel Pharmaceuticals | $750,000.00 | 7.94 | -$3.00 million | ($3.64) | -0.25 |
Ferguson has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Ferguson, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ferguson and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ferguson | 6.82% | 37.24% | 12.31% |
| Cyclacel Pharmaceuticals | -118.27% | -31.60% | -27.72% |
Summary
Ferguson beats Cyclacel Pharmaceuticals on 13 of the 15 factors compared between the two stocks.
About Ferguson
Ferguson Enterprises Inc. distributes plumbing and heating products in North America. The company provides expertise, solutions, and products, including infrastructure, plumbing, appliances, fire, and fabrication, as well as heating, ventilation, and air conditioning (HVAC) to residential and non-residential customers. It also supplies specialist water and wastewater treatment products to residential, commercial, and infrastructure contractors, as well as supplies pipe, valves, and fittings solutions to industrial customers. In addition, it offers customized solutions, such as virtual design, fabrication, valve actuation, pre-assembly, kitting, installation, and project management services, as well as after-sales support that comprises warranty, credit, project-based billing, returns and maintenance, and repair and operations support. The company sells its products through a network of distribution centers, branches, counter service and specialist sales associates, showroom consultants, and e-commerce channels. Ferguson Enterprises Inc. was founded in 1953 and is headquartered in Newport News, Virginia.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.